Skip to Content

Erythromycin Ethylsuccinate and Sulfisoxazole Oral Suspension

Last Updated: July 17, 2014
Status: Discontinued

Products Affected - Description

E.S.P oral suspension, 200 mg/5 mL erythromycin ethylsuccinate / 600 mg/5 mL sulfisoxazole, Teva
100 mL bottle (NDC 51285-0445-22) - discontinued
150 mL bottle (NDC 51285-0445-21) - discontinued
200 mL bottle (NDC 51285-0445-23) - discontinued

Reason for the Shortage

  • Teva has discontinued all E.S.P. suspension. The 150 mL bottles were discontinued in June 2014, the 100 mL bottles were discontinued in January 2014, and the 200 mL bottles were discontinued in September 2013.
  • Teva discontinued all generic erythromycin ethylsuccinate and sulfisoxazole suspension in July 2012.
  • There are no other manufacturers of the combination erythromycin ethylsuccinate and sulfisoxazole suspension.

Available Products

There are no presentations available.

Estimated Resupply Dates

All combination erythromycin ethylsuccinate and sulfisoxazole suspensions were discontinued.

Related Shortages

Updated

July 17, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide